IRIS
LEONETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.098
NA - Nord America 1.051
AS - Asia 454
AF - Africa 20
SA - Sud America 4
OC - Oceania 3
Totale 2.630
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.042
IT - Italia 362
IE - Irlanda 262
SG - Singapore 260
SE - Svezia 237
CN - Cina 136
DE - Germania 47
FR - Francia 32
FI - Finlandia 28
IN - India 27
AT - Austria 22
NL - Olanda 21
CI - Costa d'Avorio 18
GB - Regno Unito 18
CZ - Repubblica Ceca 16
BE - Belgio 13
CA - Canada 8
RU - Federazione Russa 7
TR - Turchia 7
HK - Hong Kong 6
IR - Iran 6
LU - Lussemburgo 6
CH - Svizzera 5
LT - Lituania 4
VN - Vietnam 4
AU - Australia 3
MD - Moldavia 3
UA - Ucraina 3
BG - Bulgaria 2
BR - Brasile 2
DK - Danimarca 2
HR - Croazia 2
KR - Corea 2
AR - Argentina 1
AZ - Azerbaigian 1
BS - Bahamas 1
EG - Egitto 1
ES - Italia 1
JP - Giappone 1
KZ - Kazakistan 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
PL - Polonia 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 2.630
Salva come PNG Salva come JPEG
Città #
Chandler 284
Dublin 259
Singapore 186
Ashburn 98
Boardman 94
Shanghai 83
Parma 79
New York 65
Princeton 38
Milan 35
Bologna 31
Chicago 28
Ann Arbor 24
Marseille 24
Helsinki 23
Vienna 22
Verona 19
Abidjan 18
Des Moines 18
Bremen 16
Rome 16
Munich 13
West Jordan 12
Amsterdam 11
Los Angeles 11
Santa Clara 11
Brno 10
Dallas 10
Fremont 10
Beijing 9
London 9
Reggio Emilia 9
Sorbolo 9
Trento 9
Wilmington 9
Brussels 7
Pune 7
Florence 6
Frankfurt am Main 6
Houston 6
Istanbul 6
Louvain-la-Neuve 6
Modena 6
Bolzano 5
Cavriago 5
Toronto 5
Verdellino 5
Ardea 4
Assago 4
Dong Ket 4
Hong Kong 4
Kochi 4
Kolkata 4
Olomouc 4
Wayne 4
Aachen 3
Borås 3
Brescia 3
Dearborn 3
Fairfield 3
Genoa 3
Jinan 3
Kyiv 3
Lonato 3
Melbourne 3
Norwalk 3
Phoenix 3
Piacenza 3
San Giuliano Milanese 3
Scandiano 3
Tehran 3
Atlanta 2
Ayr 2
Bhubaneswar 2
Central 2
Chisinau 2
Clifton 2
Créteil 2
Daejeon 2
Dietikon 2
Falls Church 2
Fidenza 2
Hangzhou 2
Hyderabad 2
Luxembourg 2
Maranello 2
Marino 2
Neviano degli Arduini 2
Noviglio 2
Ottawa 2
Prague 2
Redmond 2
Rio Saliceto 2
Salsomaggiore Terme 2
Seattle 2
Shijiazhuang 2
Sissa 2
Sofia 2
Sondrio 2
Stockholm 2
Totale 1.810
Salva come PNG Salva come JPEG
Nome #
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 87
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 78
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 76
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 76
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 75
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 73
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 66
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 66
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 66
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 64
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 64
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 64
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 59
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 57
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 57
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 56
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 53
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 53
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? 50
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 49
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? 49
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 49
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 47
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors 47
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 47
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 46
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 45
227P Sexual dimorphism in immune profile of early and advanced NSCLC 45
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 45
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 44
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression 44
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 43
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 41
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 41
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 40
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? 40
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) 39
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 38
Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition? 35
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 33
Small cell lung cancer: Novel treatments beyond immunotherapy 31
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 31
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 31
Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series 31
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 31
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 31
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 27
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 25
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 25
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 25
The role of the microbiome in cancer and therapy efficacy: Focus on lung cancer 23
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 23
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 21
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 20
The link between calcitriol and anticancer immunotherapy: Vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade 20
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 19
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 19
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 18
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 16
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 16
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 15
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 14
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 13
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 12
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 12
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 12
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 11
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 10
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 5
Totale 2.734
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.774
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.774
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 0 0 0 0 4 3 2 0 0 3 0 0
2020/202165 0 0 0 8 5 8 5 8 10 5 2 14
2021/2022276 9 4 33 19 2 6 77 15 4 0 27 80
2022/20231.046 111 126 43 87 112 112 20 57 305 3 48 22
2023/2024754 37 49 34 26 74 128 85 35 53 56 60 117
2024/2025581 63 125 155 149 89 0 0 0 0 0 0 0
Totale 2.734